Noom
Psychology-driven digital weight management platform combining behavioral coaching with GLP-1 medication prescribing, valued at $3.7B.
What we like
What to watch
Full Review
Noom occupies a distinctive position in the telehealth weight-loss market by anchoring its GLP-1 prescribing program to a mature behavioral-change platform with 18 years of iteration and nearly 850,000 App Store reviews averaging 4.7 stars. The company's introduction of a microdose GLP-1 tier at $199/month and a taper-off guarantee represent genuine product innovation. However, Noom's history of billing controversies — including a $56M class action settlement and a BBB 'D' rating — remains a material reputational liability, and its coaching experience is frequently criticized as automated rather than clinical-grade. The $3.7B valuation reflects investor confidence in Noom's brand and data moat, but the company's refusal to expand beyond weight loss limits its addressable market compared to multi-vertical competitors.
Last researched: 2026-03-30
Pricing
| Treatment | Category | Price/mo | Includes | Notes |
|---|---|---|---|---|
| Noom Weight (Behavioral Only) | Weight Loss / GLP-1 | $17–$59 | ○ Consults○ Lab work○ Shipping | Free 7-14 day trial Subscription required |
| Noom Med GLP-1 Rx (Compounded Semaglutide) | Weight Loss / GLP-1 | $129–$279 | ● Consults● Lab work● Shipping | $129 first month Subscription required |
| Noom Microdose GLP-1 Rx | Weight Loss / GLP-1 | $99–$199 | ● Consults○ Lab work● Shipping | $99 first month Subscription required |
| Noom Med Brand-Name Rx Access | Weight Loss / GLP-1 | $69 | ● Consults○ Lab work○ Shipping | Medication cost separate (insurance-dependent) Subscription required |